Posts tagged NDQ
Stryker to acquire Novadaq Technologies

Stryker (NYSE:SYK) has agreed to acquire Novadaq Technologies (NASDAQ:NVDQ; TSX:NDQ) for $11.75 a share, implying a total equity value of approximately $701-million.

Read More
Appeals court upholds LifeNet’s patent victory

The U.S. Court of Appeals for the Federal Circuit upheld a Virginia federal jury award to LifeNet Health of $34.7-million in damages for LifeCell's infringement of a LifeNet patent related to improving the preservation of tissue grafts.

In November 2014, a jury found that LifeCell's AlloDerm Ready to Use Regenerative Tissue Matrix and Strattice skin graft products infringed all seven asserted claims of LifeNet's patent.

Read More
Scotiabank starts Novadaq at sector outperform

Scotiabank initiated coverage of Novadaq Technologies (NASDAQ:NVDQ; TSX:NDQ) with a “sector outperform” rating and a one-year price target of $18.  The stock closed at $11.43 on Tuesday.

Analyst Alan Ridgeway writes that at a multiple of eight times estimated 2017 sales, “Novadaq would trade at a premium to peers, which is justified, in our opinion, because we believe it will break even in roughly 12 months and has the potential to grow more than 30% annually through 2020.”

Read More
Karen Licitra to join Novadaq board

Novadaq Technologies (NASDAQ:NVDQ; TSX:NDQ) said Karen Licitra will be joining the company’s board of directors. 

Ms. Licitra has a track record of accomplishments in sales, marketing, commercial and general management in the global healthcare industry. In her 30-plus-year career with Johnson & Johnson (NYSE:JNJ), she most recently served as corporate VP worldwide government affairs and policy, before retiring in August 2015. 

Read More
Feltl upgrades Novadaq to strong buy

Feltl & Co. upgraded Novadaq Technologies (NASDAQ:NVDQ; TSX:NDQ) to “strong buy” from “buy” after the company posted second quarter revenue ahead of expectations yesterday on the strength of its direct sales business.

Analyst Ben Haynor maintained his price target of $15 on Novadaq. The stock was quoted $10.13, up $1.30, at mid-day Thursday.

Read More
Novadaq Q2 revenue climbs 34%

Novadaq Technologies (NASDAQ:NVDQ; TSX:NDQ) reported revenue of $20.1-million in the second quarter, an increase of 34% from $15.1-million a year ago.

Total direct sales in the latest quarter increased by $4.4-million, or 37%, and total partnered/international sales rose by $600,000, or 21%, compared with the same period last year.

Read More
Novadaq posts 52% jump in Q1 revenue

Novadaq Technologies (NASDAQ:NVDQ; TSX:NDQ) has reported first quarter revenue of $17.7-million, up 52%, from $11.7-million a year ago.

Total direct sales in the quarter rose by $6.1-million, or 71%, and total partnered/international sales declined by $100,000, compared with the year earlier period.

Read More
Novadaq posts 54% jump in Q4 revenue

Novadaq Technologies (NASDAQ:NVDQ; TSX:NDQ) has reported revenue of $20-million for the final quarter of 2015, up 54% from $13-million in the year earlier quarter, and up 18% from the third quarter of 2015.

Product sales increased by $9.3-million, or 95%, primarily due to an 89% increase in capital sales and a 107% increase in recurring revenue.

Read More
Novadaq Q4 revenue to jump about 54%

Novadaq Technologies (NASDAQ:NVDQ; TSX:NDQ) has released preliminary unaudited revenue for the fourth quarter of 2015 of approximately $20-million, reflecting increases of about 54% from $13-million in the 2014 fourth quarter and 18% sequentially over $17-million in the third quarter last year.

For all of 2015, the company anticipates total revenues to be approximately $63.8-million, representing total year-over-year revenue growth of about 37%.

Read More
JMP resumes coverage of Novadaq at outperform

JMP Securities has resumed coverage of Novadaq Technologies (NASDAQ:NVDQ; TSX:NDQ) with a “market outperform” rating and $16 price target. The stock closed at $13.50 on Tuesday.

“Novadaq was once highly regarded within the small cap MedTech world, but its shares were driven down from historical highs by what we believe were overblown concerns around competition and a challenging transition to direct sales of SPY Elite, which is now in the company’s rearview mirror,” writes analyst John Gillings.

Read More